Black Diamond’s BDTX-1535 shows promising clinical activity in Phase 1 GBM trial
The fourth generation BDTX-1535 is an oral, brain-penetrant, covalent EGFR inhibitor, which is currently in Phase 1 clinical…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Dec 23
The fourth generation BDTX-1535 is an oral, brain-penetrant, covalent EGFR inhibitor, which is currently in Phase 1 clinical…
14 Dec 23
Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY
13 Dec 23
The acquisition will strengthen AstraZeneca’s vaccines and immune therapies pipeline with Icosavax’s lead investigational vaccine candidate IVX-A12, a…
13 Dec 23
The collaboration is aimed at developing new gene therapies for undisclosed CNS diseases by leveraging JCR Pharmaceuticals' proprietary…
13 Dec 23
The trial assessed Darzalex SC formulation-based quadruplet induction, consolidation regimen and doublet maintenance regimen in patients with transplant-eligible…
13 Dec 23
Funding comes on the heels of positive top-line clinical results and will advance clinical development of its lead…
12 Dec 23
The merger will combine Sigma’s distribution infrastructure and CWG’s retailing know-how to create a full-service wholesaler, distributor, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 Dec 23
The authorisation of the indication also converts previous conditional approval for Jemperli to full approval as a monotherapy…
12 Dec 23
BL-B01D1 is a bispecific topoisomerase inhibitor-based ADC, which is presently in a Phase 1 study in patients with…
12 Dec 23
The financing will be used to optimize breakthrough applications of the company’s Z-Screen platform and advance an internal…